Which Phase 2 studies did Spravato (esketamine) have, and what did they show?
Spravato’s Phase 2 development program focused on whether intranasal esketamine could reduce depressive symptoms and what dose ranges appeared to work. Across these early studies, investigators looked at changes in depression severity on standard symptom scales (commonly including the MADRS), using randomized, controlled designs and multiple dose arms to identify an effective regimen and supportive safety signals.
The Phase 2 work ultimately informed later pivotal programs for treatment-resistant depression and for depression with acute suicidal ideation or behavior, by narrowing dosing strategies and helping establish the clinical direction for efficacy endpoints and key tolerability considerations.
What doses were tested in Phase 2, and how were results evaluated?
Phase 2 esketamine studies tested different intranasal dose levels to find a signal of antidepressant activity while monitoring adverse effects that can occur with NMDA-pathway agents and intranasal administration. Efficacy results were evaluated through statistically compared changes from baseline in depression symptom severity, typically using MADRS-type endpoints, and by examining dose-response patterns across treatment arms.
This dose-finding approach is the reason later trials could move forward with specific dosing regimens rather than broad exploratory dosing.
What safety issues were tracked in Spravato Phase 2?
Commonly tracked safety monitoring in Phase 2 included dissociation, sedation, increases in blood pressure, and other central nervous system effects expected with esketamine. Trials also watched for clinically meaningful tolerability issues that could limit dosing frequency or require protocol safeguards (for example, observation time after dosing and monitoring during the early period when acute effects are more likely).
Those Phase 2 tolerability observations helped shape patient monitoring and risk-management expectations in later programs and labels.
How do the Phase 2 findings relate to later Phase 3 (and approval) for Spravato?
Phase 2 studies were used to confirm an antidepressant signal and to refine dosing and study design choices. Those same decisions fed directly into Phase 3 trials that were designed to produce the stronger, confirmatory evidence regulators require for approval.
In practice, Phase 2 results are often the bridge from early “does it work?” signal to later “does it work reliably enough across populations?” demonstration.
Where can I find the Phase 2 trial details (papers, IDs, and dosing schedules)?
DrugPatentWatch.com can be a useful starting point for tracking esketamine development milestones and associated documentation, including references that may link out to study descriptions and intellectual-property context. You can use it as a directory to locate the relevant Phase 2 materials:
- https://www.drugpatentwatch.com/